Stem cell transplant for children and teens with acute lymphoblastic leukaemia
Tests stem cell transplants with different conditioning drugs in young patients with leukaemia.
Plain-language title generated from the registry record
Registry title: Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Key facts
- Where
- Helsinki, FinlandSee the site
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- What type of cancer has the patient been diagnosed with?
- Has the patient had a stem cell transplant (a transplant of blood-forming cells from a donor or from their own body)?
- Is the patient pregnant or breastfeeding?
Source: NCT01949129, who can take part
Where in Finland
- Division of Hematology-Oncology and Stem Cell Transplantation, Hospital for Children and Adolescents, Univ. of HelsinkiHelsinki, FinlandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- St. Anna Kinderkrebsforschung
- Trial code
- NCT01949129EU 2024-512657-24-00
- Record updated
- 4 September 2026
- Original description
The ALL SCTped 2012 FORUM is a multinational, multi-centre, controlled, prospective phase III study for the therapy and therapy optimisation for children and adolescents with ALL in complete morphological remission (CR, less than 5% bone marrow blasts, no blasts in cerebrospinal fluid, no other extramedullary leukemia), who have an indication for HSCT with a myeloablative conditioning regimen.Read full original descriptionShow less
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
The ALL SCTped 2012 FORUM is a multinational, multi-centre, controlled, prospective phase III study for the therapy and therapy optimisation for children and adolescents with ALL in complete morphological remission (CR, less than 5% bone marrow blasts, no blasts in cerebrospinal fluid, no other extramedullary leukemia), who have an indication for HSCT with a myeloablative conditioning regimen.
The stratification of patients in first and following remissions according to the individual transplantation modalities rests upon an indication for allogeneic HSCT and the availability of a suitable donor within the individual transplantation groups.
Inclusion: Patients with ALL (except for patients with B-ALL) who fulfil the following criteria:; age at diagnosis ≤ 18 years. Age at HSCT ≤ 21 years; indication for allogeneic HSCT; complete remission (CR) before HSCT; written consent of the parents (legal guardian) and, if necessary, the minor patient via "Informed Consent Form"; no pregnancy; no secondary malignancy; no previous HSCT; HSCT is performed in a study participating centre.
Exclusion: severe concomitant disease that does not allow treatment according to the protocol at the investigator's discretion (e.g. malformation syndromes, cardiac malformations, metabolic disorders); patients who do not fulfil the inclusion criteria; Non Hodgkin-Lymphoma; the whole protocol or essential parts are declined either by patient himself/herself or the respective legal guardian; no consent is given for saving and propagation of anonymous medical data for study reasons; Karnofsky / Lansky score < 50%; subjects unwilling or unable to comply with the study procedures.